Marstacimab is a human Monoclonal Antibody Directed Against Tissue Factor Pathway Inhibitor currently being developed by Pfizer for the treatment of hemophilia A and hemophilia B.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.